Buy, Sell, Hold: 6 stocks on analysts' radar today

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Kotak Securities said IRB Infrastructure's Amritsar-Pathankot project sale consideration 8 percent was ahead of its estimates but the transaction would not change target price for company.

Transaction would reduce net-debt to equity for company to 1.5x by FY18 end, it feels.

The research house has add rating for the company with target at Rs 225 per share.

PhillipCap said Titan has indicated that new store openings would pickup pace in second half of FY18.

Watches witnessed good growth in the quarter aided by exceptional sales. Response to the Titan ‘activation’ was decent but was below expectations, the research house said.

"Titan Eye Plus continues to show healthy growth," it said.

CLSA has also retained buy call on Titan on aggressive guidance for second half of FY18.

Market-share gains continued in jewellery, which remains the big story, it feels.

CLSA said, however, lacklustre quarter is likely on sale advancement and regulatory issue in Q2. "We forecast a 2 percent YoY growth in pre-ex earnings during Q2," it said.

BOBCAPS has a buy call on GAIL with a target price of Rs 490 per share.

Petroleum & Natural Gas Regulatory Board Of India has floated consultation paper w.r.t unified tariff for company’s pipelines Rs 57 per mmbtu.

The brokerage house feels proposed tariff rate by PNGRB was 60 percent higher than current levels and proposed rate offers a massive 45 percent upside to company's earnings

Tariff could be major re-rating for the stock, according to BOBCAPS.

Morgan Stanley remained overweight on Biocon with a target price of Rs 434 per share after US-based biotechnology company Amgen Inc announced global settlement with AbbVie Inc with respect to Amgevitatm.

Amgen can now enter EU & US markets to market Amgevitatm.

Company is filing its dossier for products sometime in FY18 will allow it to launch in US by 2023.

US FDA/EMA progress at Bengaluru unit is a key monitorable, it feels.

While having a buy call on Bharti Infratel with a target price of Rs 470 per share,, Citi said expectation of exit from Indus Tower led to hope of return on equity accretion if company exercises right of first refusal.

Nomura said it has reduce rating on Wipro with a target price of Rs 220 per share as past buyback trends suggest a fall-off is likely.